The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
FDA Grants Priority Review to Darolutamide/Docetaxel in Metastatic Hormone-Sensitive Prostate CancerMay 3rd 2022
The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Enzalutamide Plus ADT Demonstrates Significant Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer
Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.
Interpreting Data From the ARASENS Trial in Metastatic HSPCApril 27th 2022
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Selecting Optimal Therapy for mHSPC: Design of the ARASENS TrialApril 27th 2022
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
FDA Authorizes IND Application for 177Lu-rhPSMA-10.1 for Metastatic Castration-Resistant Prostate CancerApril 13th 2022
The FDA has cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer.
Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life MeasuresApril 13th 2022
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPCApril 12th 2022
Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.
Genetically Adjusting PSA May Improve Screening with PSA Alone in Prostate CancerApril 11th 2022
The genetic adjustment of prostate-specific antigen could reduce over-diagnosis, de-escalate invasive testing, and improve the detection of aggressive disease in patients with prostate cancer.
Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPCApril 6th 2022
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Evolving Treatment Landscape of Nonmetastatic CRPCApril 6th 2022
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Optimizing Use of PSMA PET Imaging and PSADT in Prostate CancerMarch 30th 2022
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
FDA Approves Pluvicto for Progressive, PSMA-Positive Metastatic CRPCMarch 23rd 2022
The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.
Continuous Enzalutamide/Docetaxel May Represent Future Option for Select mCRPC Who Progress on Enzalutamide Alone
Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.